Yamaguchi Shinji, Zhorov Boris S, Yoshioka Katsuro, Nagao Taku, Ichijo Hidenori, Adachi-Akahane Satomi
Laboratory of Cell Signaling, Graduate school of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.
Mol Pharmacol. 2003 Aug;64(2):235-48. doi: 10.1124/mol.64.2.235.
Voltage-dependent L-type Ca2+ channels are modulated by the binding of Ca2+ channel antagonists and agonists to the pore-forming alpha1c subunit (CaV 1.2). We recently identified Ser1115 in IIIS5-S6 linker of alpha1C subunit as a critical determinant of the action of 1,4-dihydropyridine agonists. In this study, we applied alanine-scanning mutational analysis in IIIS5-S6 linker of rat brain alpha1C subunit (rbCII) to illustrate the role of pore-forming IIIS5-S6 linker in the action of Ca2+ channel modulators. Ca2+ channel currents through wild-type (rbCII) or mutated alpha1C subunits, transiently expressed in BHK6 cells with beta1a and alpha2/delta subunits, were analyzed. The replacement of Phe1112 by Ala (F1112A) significantly impaired the sensitivity to Ca2+ channel agonists (S)-(-)-Bay k 8644 and FPL-64176, and modestly to 1,4-dihydropyridine (DHP) antagonists. The low sensitivity of F1112A and S1115A to DHP antagonists was consistent with the reduced binding affinity for 3HPN200-110. The replacement of Phe1112 by Tyr, but not by Ala, restored the long openings produced by FPL-64176, thus indicating the critical role of aromatic ring of Phe1112 in the Ca2+ channel agonist action. Interestingly, double-mutant Ca2+ channel (F1112A/S1115A) failed to discriminate between Ca2+ channel agonist (S)-(-)-1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-[trifluoromethyl] phenyl)-3-pyridine carboxylic acid methyl ester (Bay k 8644) and antagonist (R)-(+)-Bay k 8644 and was blocked by the two enantiomers in an identical manner. These results indicate that both Phe1112 and Ser1115 in linker IIIS5-S6 are required for the action of Ca2+ channel agonists. A model of the DHP receptor is proposed to visualize possible interactions of Phe1112, Ser1115, and other DHP-sensing residues with a typical DHP ligand nifedipine.
电压依赖性L型Ca2+通道受Ca2+通道拮抗剂和激动剂与形成孔道的α1c亚基(CaV 1.2)结合的调节。我们最近确定α1C亚基IIIS5-S6连接区中的Ser1115是1,4-二氢吡啶激动剂作用的关键决定因素。在本研究中,我们对大鼠脑α1C亚基(rbCII)的IIIS5-S6连接区进行丙氨酸扫描突变分析,以阐明形成孔道的IIIS5-S6连接区在Ca2+通道调节剂作用中的作用。分析了在BHK6细胞中与β1a和α2/δ亚基瞬时共表达的野生型(rbCII)或突变型α1C亚基的Ca2+通道电流。用丙氨酸取代苯丙氨酸1112(F1112A)显著损害了对Ca2+通道激动剂(S)-(-)-Bay k 8644和FPL-64176的敏感性,对1,4-二氢吡啶(DHP)拮抗剂的敏感性也有一定程度的降低。F1112A和S1115A对DHP拮抗剂的低敏感性与对[3H]+PN200-110的结合亲和力降低一致。用酪氨酸而非丙氨酸取代苯丙氨酸1112恢复了FPL-64176产生的长开放时间,从而表明苯丙氨酸1112的芳香环在Ca2+通道激动剂作用中的关键作用。有趣的是,双突变Ca2+通道(F1112A/S1115A)无法区分Ca2+通道激动剂(S)-(-)-1,4-二氢-2,6-二甲基-5-硝基-4-(2-[三氟甲基]苯基)-3-吡啶羧酸甲酯(Bay k 8644)和拮抗剂(R)-(+)-Bay k 8644,且被这两种对映体以相同方式阻断。这些结果表明,IIIS5-S6连接区中的苯丙氨酸1112和丝氨酸1 Ser1115都是Ca2+通道激动剂发挥作用所必需的。提出了DHP受体模型,以可视化苯丙氨酸1112、丝氨酸1115和其他DHP感受残基与典型DHP配体硝苯地平可能的相互作用。